Immuneering (IMRX)

• Market cap: $44.9M
• 1 day: -7.41%
• 5 days: -18.83%
• 1 month: -14.38%
• 3 months: -37.50%
• 6 months: -47.70%
• Year to date: -43.44%
• 1 year: -41.04%
• 5 years: -92.89%
• 10 years: -92.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Employees: 66

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 38 [Q3] → 42 (+4) [Q4]

0.84% less ownership

Funds ownership: 14.7% [Q3] → 13.86% (-0.84%) [Q4]

14% less capital invested

Capital invested by funds: $10.9M [Q3] → $9.32M (-$1.55M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 860% upside
• Avg. target: $12.50 900% upside
• High target: $13 940% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Geulah Livshits 5% 1-year accuracy 3 / 59 met price target	940% upside $13	Buy Maintained	24 Mar 2025
Needham Ami Fadia 17% 1-year accuracy 29 / 174 met price target	860% upside $12	Buy Reiterated	21 Mar 2025